^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 expression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study (clinicaltrials.gov)
    P=N/A, N=600, Active, not recruiting, University Hospital, Basel, Switzerland
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    1d
    A multicenter, single-arm phase II clinical study of eribulin combined with inituzumab and pyrotinib in the treatment of HER2-positive advanced breast cancer (ChiCTR2600121825)
    P2, N=76, Recruiting, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Irene (pyrotinib) • Halaven (eribulin mesylate) • TheraCIM (nimotuzumab)
    1d
    Phase II, Single-Arm, Single-Center, Interventional Study of Vedolizumab in High-Risk Non-Muscle Invasive Bladder Cancer with HER-2 Expression (ChiCTR2600121526)
    P2, N=100, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden)
    |
    HER-2 expression
    |
    Entyvio (vedolizumab)
    1d
    A Prospective, Single-Arm, Multicenter, Open-Label Phase II Clinical Study of Cadonilimab + Disitamab Vedotin ± Bevacizumab Combined with Radiotherapy in the Treatment of Locally Advanced or Stage IVB Cervical Cancer with Oligometastases (ChiCTR2600120786)
    P2, N=147, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    1d
    A multicentre randomised controlled study to evaluate the efficacy of bladder-preserving therapy with oral probiotics combined with PD-1 monoclonal antibody and Disitamab Vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and low serum butyrate (ChiCTR2600120506)
    P=N/A, N=146, Sun Yat-sen Memorial Hospital,Sun Yat-sen University; Sun Yat-sen Memorial Hospital,Sun Yat-sen University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Entyvio (vedolizumab)
    1d
    Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial (ChiCTR2600120346)
    P4, N=40, Recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Halaven (eribulin mesylate)
    2d
    Exploration of the Value of Tumor Hyperthermia in First-Line Treatment of Gastroesophageal Junction Cancer (ChiCTR2600119875)
    P=N/A, N=200, Completed, Changzhi People's Hospital; Changzhi People's Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    2d
    Real-World Study on the Efficacy and Safety of Zanidatamab in the Treatment of Patients with HER2-Expressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer (ChiCTR2600119329)
    P=N/A, N=30, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Ziihera (zanidatamab-hrii)
    2d
    Efficacy and safety of SHR-1811-based combination regimens in advanced HER2-overexpressing urothelial carcinoma: a single-center, multi-cohort, Exploratory research (ChiCTR2600118801)
    P=N/A, N=45, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811)
    2d
    Clinical translational research on the integration of diagnosis and treatment of Her2-positive breast cancer with dual-mode radionuclide/fluorescence drugs (ChiCTR2600118518)
    P=N/A, N=20, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Herceptin (trastuzumab)
    3d
    EMP3 Expression in HER2-Enriched Breast Cancer is Linked to PI3K/AKT Signaling and Indicates Poor Prognosis. (PubMed, Genet Res (Camb))
    High EMP3 expression in HER2-enriched breast cancer predicts poor patient outcomes. Overexpression of EMP3 exerts an upregulatory effect on the PI3K-AKT pathway and boosts the development of trastuzumab resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 expression
    |
    Herceptin (trastuzumab)
    3d
    Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. (PubMed, Mol Cancer Ther)
    HER2 expression is relatively low in this HNSCC cohort compared to other ADC targets, but there are 39.1% of cases with detectable HER2 exceeding historical estimates. Overall, ADC target levels in HNSCC for approved ADCs suggests that HNSCC patients may benefit from this class of drugs.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 expression • EGFR expression • EGFR positive